location_id,location,disease,time,age_group_id,age_group,age,is_filled,gender_id,gender,measure_id,measure,mean,lower,upper
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,1,FALSE,1,Male,5,Prevalence,1.3143419852833818E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,2,TRUE,1,Male,5,Prevalence,2.2250219644843747E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,3,TRUE,1,Male,5,Prevalence,3.891615436486111E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,4,TRUE,1,Male,5,Prevalence,6.713805522801296E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,1,FALSE,1,Male,6,Incidence,1.3143419852833818E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,2,TRUE,1,Male,6,Incidence,1.2873490846022641E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,3,TRUE,1,Male,6,Incidence,2.3132316541259045E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,4,TRUE,1,Male,6,Incidence,3.972366095863729E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,1,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,2,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,3,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,4,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,1,TRUE,1,Male,15,mortality,0.2837167228215407,0.32183134629350074,0.32183134629350074
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,2,TRUE,1,Male,15,mortality,0.28658378711689836,0.32281704784162524,0.32281704784162524
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,3,TRUE,1,Male,15,mortality,0.2906210308476791,0.32393988640875326,0.32393988640875326
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,4,TRUE,1,Male,15,mortality,0.29555232598423475,0.32519448485443403,0.32519448485443403
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,1,FALSE,2,Female,5,Prevalence,1.1003271042253922E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,2,TRUE,2,Female,5,Prevalence,1.8640888701931306E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,3,TRUE,2,Female,5,Prevalence,3.2627640789544437E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,4,TRUE,2,Female,5,Prevalence,5.633160286556779E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,1,FALSE,2,Female,6,Incidence,1.1003271042253922E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,2,TRUE,2,Female,6,Incidence,1.1990516924971112E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,3,TRUE,2,Female,6,Incidence,2.1444074770551927E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,4,TRUE,2,Female,6,Incidence,3.69317331091858E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,1,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,2,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,3,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,4,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,1,TRUE,2,Female,15,mortality,0.3924099175874692,0.46047478237044437,0.46047478237044437
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,2,TRUE,2,Female,15,mortality,0.39560047511186136,0.45734937857365365,0.45734937857365365
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,3,TRUE,2,Female,15,mortality,0.40005188391004737,0.45461885396946633,0.45461885396946633
826,United Kingdom,Gallbladder and biliary tract cancer,2019,5,1 to 4,4,TRUE,2,Female,15,mortality,0.4054161009674279,0.4522724665495811,0.4522724665495811
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,5,FALSE,1,Male,5,Prevalence,1.128426105479781E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,6,TRUE,1,Male,5,Prevalence,1.842892816004303E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,7,TRUE,1,Male,5,Prevalence,2.9243207056591554E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,8,TRUE,1,Male,5,Prevalence,4.511484066611589E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,9,TRUE,1,Male,5,Prevalence,6.77243808598291E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,5,FALSE,1,Male,6,Incidence,6.591767320901858E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,6,TRUE,1,Male,6,Incidence,1.0607363373154447E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,7,TRUE,1,Male,6,Incidence,1.6576214880934423E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,8,TRUE,1,Male,6,Incidence,2.5177998274640462E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,9,TRUE,1,Male,6,Incidence,3.720241678643085E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,5,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,6,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,7,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,8,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,9,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,5,TRUE,1,Male,15,mortality,0.3010679617967427,0.32657546603821663,0.32657546603821663
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,6,TRUE,1,Male,15,mortality,0.30686069131134747,0.32807745281965006,0.32807745281965006
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,7,TRUE,1,Male,15,mortality,0.312657124,0.3296950680582835,0.3296950680582835
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,8,TRUE,1,Male,15,mortality,0.31824019543482374,0.3314229346136659,0.3314229346136659
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,9,TRUE,1,Male,15,mortality,0.32346063288430754,0.3332556753453464,0.3332556753453464
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,5,FALSE,2,Female,5,Prevalence,9.475194447279997E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,6,TRUE,2,Female,5,Prevalence,1.5486097115774285E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,7,TRUE,2,Female,5,Prevalence,2.4590770973532207E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,8,TRUE,2,Female,5,Prevalence,3.795990669040913E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,9,TRUE,2,Female,5,Prevalence,5.7007014478490295E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,5,FALSE,2,Female,6,Incidence,6.158991833792287E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,6,TRUE,2,Female,6,Incidence,9.965350212893353E-09,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,7,TRUE,2,Female,6,Incidence,1.565855887418231E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,8,TRUE,2,Female,6,Incidence,2.390995859583333E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,9,TRUE,2,Female,6,Incidence,3.550301826148244E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,5,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,6,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,7,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,8,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,9,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,5,TRUE,2,Female,15,mortality,0.4113068900069772,0.45029947430569683,0.45029947430569683
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,6,TRUE,2,Female,15,mortality,0.41734736653458543,0.4486891352295129,0.4486891352295129
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,7,TRUE,2,Female,15,mortality,0.42321087908318605,0.44743070731272805,0.44743070731272805
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,8,TRUE,2,Female,15,mortality,0.42864952474802426,0.44651344854704134,0.44651344854704134
826,United Kingdom,Gallbladder and biliary tract cancer,2019,6,5 to 9,9,TRUE,2,Female,15,mortality,0.4335076284544117,0.4459266169241516,0.4459266169241516
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,10,FALSE,1,Male,5,Prevalence,9.901643215002093E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,11,TRUE,1,Male,5,Prevalence,1.4113995579068554E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,12,TRUE,1,Male,5,Prevalence,1.9636346062424022E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,13,TRUE,1,Male,5,Prevalence,2.6697962655821795E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,14,TRUE,1,Male,5,Prevalence,3.552215500729366E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,10,FALSE,1,Male,6,Incidence,5.3521744892140124E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,11,TRUE,1,Male,6,Incidence,7.505152005252332E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,12,TRUE,1,Male,6,Incidence,1.027067130118635E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,13,TRUE,1,Male,6,Incidence,1.3736433303600205E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,14,TRUE,1,Male,6,Incidence,1.798450060990821E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,10,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,11,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,12,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,13,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,14,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,10,TRUE,1,Male,15,mortality,0.3282376257264075,0.335187913,0.335187913
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,11,TRUE,1,Male,15,mortality,0.33255075208764745,0.3372142707757977,0.3372142707757977
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,12,TRUE,1,Male,15,mortality,0.3364263040630872,0.3393293711936668,0.3393293711936668
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,13,TRUE,1,Male,15,mortality,0.3399213882078464,0.3415278372260303,0.3415278372260303
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,14,TRUE,1,Male,15,mortality,0.3431087073958275,0.343804292,0.343804292
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,10,FALSE,2,Female,5,Prevalence,8.33569284165582E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,11,TRUE,2,Female,5,Prevalence,1.1878210205243353E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,12,TRUE,2,Female,5,Prevalence,1.651091361654889E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,13,TRUE,2,Female,5,Prevalence,2.2410571590573273E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,14,TRUE,2,Female,5,Prevalence,2.973659544042398E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,10,FALSE,2,Female,6,Incidence,5.13030642694096E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,11,TRUE,2,Female,6,Incidence,7.22107997321447E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,12,TRUE,2,Female,6,Incidence,9.910497649511637E-08,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,13,TRUE,2,Female,6,Incidence,1.327836530568287E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,14,TRUE,2,Female,6,Incidence,1.7391634210935002E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,10,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,11,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,12,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,13,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,14,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,10,TRUE,2,Female,15,mortality,0.43772064955484397,0.44565947043575815,0.44565947043575815
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,11,TRUE,2,Female,15,mortality,0.4413024900962128,0.44570126707355984,0.44570126707355984
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,12,TRUE,2,Female,15,mortality,0.44432561554489086,0.44604126482925555,0.44604126482925555
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,13,TRUE,2,Female,15,mortality,0.4468986581023225,0.4466687216945445,0.4466687216945445
826,United Kingdom,Gallbladder and biliary tract cancer,2019,7,10 to 14,14,TRUE,2,Female,15,mortality,0.44914545900085967,0.44757289566112557,0.44757289566112557
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,15,FALSE,1,Male,5,Prevalence,4.632165575659427E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,16,TRUE,1,Male,5,Prevalence,5.930008087580343E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,17,TRUE,1,Male,5,Prevalence,7.466073087996217E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,18,TRUE,1,Male,5,Prevalence,9.26222122911478E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,19,TRUE,1,Male,5,Prevalence,1.1343816608633534E-06,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,15,FALSE,1,Male,6,Incidence,2.3092448887830205E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,16,TRUE,1,Male,6,Incidence,2.9138085474574425E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,17,TRUE,1,Male,6,Incidence,3.6207462159432553E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,18,TRUE,1,Male,6,Incidence,4.4404882425722276E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,19,TRUE,1,Male,6,Incidence,5.38626308734262E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,15,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,16,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,17,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,18,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,19,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,15,TRUE,1,Male,15,mortality,0.3460640249182528,0.34615335757243615,0.34615335757243615
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,16,TRUE,1,Male,15,mortality,0.3488572805565389,0.348569658,0.348569658
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,17,TRUE,1,Male,15,mortality,0.35154742415748896,0.35104781469140833,0.35104781469140833
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,18,TRUE,1,Male,15,mortality,0.35418040447584054,0.3535824516894793,0.3535824516894793
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,19,TRUE,1,Male,15,mortality,0.3567894392934589,0.356168191,0.356168191
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,15,FALSE,2,Female,5,Prevalence,3.862179567694768E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,16,TRUE,2,Female,5,Prevalence,4.916790830387092E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,17,TRUE,2,Female,5,Prevalence,6.144803467010292E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,18,TRUE,2,Female,5,Prevalence,7.551713039194515E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,19,TRUE,2,Female,5,Prevalence,9.143019243641996E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,15,FALSE,2,Female,6,Incidence,2.2302008127647886E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,16,TRUE,2,Female,6,Incidence,2.8047045736083216E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,17,TRUE,2,Female,6,Incidence,3.465537964280059E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,18,TRUE,2,Female,6,Incidence,4.215596268935822E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,19,TRUE,2,Female,6,Incidence,5.059042799107083E-07,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,15,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,16,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,17,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,18,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,19,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,15,TRUE,2,Female,15,mortality,0.4511882096975847,0.4487430447206977,0.4487430447206977
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,16,TRUE,2,Female,15,mortality,0.4531359034487646,0.45016842686496006,0.45016842686496006
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,17,TRUE,2,Female,15,mortality,0.4550780582114317,0.45183830008561154,0.45183830008561154
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,18,TRUE,2,Female,15,mortality,0.45708282151407637,0.45374192237435096,0.45374192237435096
826,United Kingdom,Gallbladder and biliary tract cancer,2019,8,15 to 19,19,TRUE,2,Female,15,mortality,0.4591981655311325,0.45586855172287777,0.45586855172287777
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,20,FALSE,1,Male,5,Prevalence,1.3741631171616108E-06,2.4002096152772717E-06,1.5581129444450604E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,21,TRUE,1,Male,5,Prevalence,1.649306765407545E-06,2.4002096152772717E-06,1.5581129444450604E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,22,TRUE,1,Male,5,Prevalence,1.9642083719352694E-06,2.4002096152772717E-06,1.5581129444450604E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,23,TRUE,1,Male,5,Prevalence,2.3237356004016565E-06,2.4002096152772717E-06,1.5581129444450604E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,24,TRUE,1,Male,5,Prevalence,2.732853230580682E-06,2.4002096152772717E-06,1.5581129444450604E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,20,FALSE,1,Male,6,Incidence,6.474751616973076E-07,7.735934168445912E-07,5.003989140970977E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,21,TRUE,1,Male,6,Incidence,7.726127816758162E-07,7.735934168445912E-07,5.003989140970977E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,22,TRUE,1,Male,6,Incidence,9.163261910363703E-07,7.735934168445912E-07,5.003989140970977E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,23,TRUE,1,Male,6,Incidence,1.0810005908238246E-06,7.735934168445912E-07,5.003989140970977E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,24,TRUE,1,Male,6,Incidence,1.2688676948106272E-06,7.735934168445912E-07,5.003989140970977E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,20,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,21,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,22,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,23,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,24,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,20,TRUE,1,Male,15,mortality,0.35939665192120146,0.3587996568605365,0.3587996568605365
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,21,TRUE,1,Male,15,mortality,0.36201529899989887,0.36147147075262087,0.36147147075262087
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,22,TRUE,1,Male,15,mortality,0.36465203794701445,0.364178256,0.364178256
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,23,TRUE,1,Male,15,mortality,0.3673089114960777,0.36691463544764613,0.36691463544764613
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,24,TRUE,1,Male,15,mortality,0.36998491393339267,0.36967523196968544,0.36967523196968544
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,20,FALSE,2,Female,5,Prevalence,1.0926610651782467E-06,2.120175352977792E-06,1.220166237608295E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,21,TRUE,2,Female,5,Prevalence,1.2915360379738255E-06,2.120175352977792E-06,1.220166237608295E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,22,TRUE,2,Female,5,Prevalence,1.512948150825147E-06,2.120175352977792E-06,1.220166237608295E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,23,TRUE,2,Female,5,Prevalence,1.759817824877282E-06,2.120175352977792E-06,1.220166237608295E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,24,TRUE,2,Female,5,Prevalence,2.0360209345660094E-06,2.120175352977792E-06,1.220166237608295E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,20,FALSE,2,Female,6,Incidence,6.002687526159601E-07,6.65639887571794E-07,3.8042605402882147E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,21,TRUE,2,Female,6,Incidence,7.05728544101917E-07,6.65639887571794E-07,3.8042605402882147E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,22,TRUE,2,Female,6,Incidence,8.238516141343268E-07,6.65639887571794E-07,3.8042605402882147E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,23,TRUE,2,Female,6,Incidence,9.567436854760374E-07,6.65639887571794E-07,3.8042605402882147E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,24,TRUE,2,Female,6,Incidence,1.1070275340085562E-06,6.65639887571794E-07,3.8042605402882147E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,20,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,21,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,22,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,23,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,24,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,20,TRUE,2,Female,15,mortality,0.4614548561389395,0.45820744612289055,0.45820744612289055
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,21,TRUE,2,Female,15,mortality,0.4638701023922292,0.46074786356608843,0.46074786356608843
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,22,TRUE,2,Female,15,mortality,0.4664511245029345,0.46347906204417055,0.46347906204417055
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,23,TRUE,2,Female,15,mortality,0.4691982098217678,0.4663902995488358,0.4663902995488358
826,United Kingdom,Gallbladder and biliary tract cancer,2019,9,20 to 24,24,TRUE,2,Female,15,mortality,0.47210709222755914,0.46947083407178314,0.46947083407178314
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,25,FALSE,1,Male,5,Prevalence,3.196083479985797E-06,2.47242849488429E-06,1.7229433170616091E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,26,TRUE,1,Male,5,Prevalence,3.7168715161704187E-06,2.47242849488429E-06,1.7229433170616091E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,27,TRUE,1,Male,5,Prevalence,4.296962615793656E-06,2.47242849488429E-06,1.7229433170616091E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,28,TRUE,1,Male,5,Prevalence,4.935917285455336E-06,2.47242849488429E-06,1.7229433170616091E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,29,TRUE,1,Male,5,Prevalence,5.63088779398953E-06,2.47242849488429E-06,1.7229433170616091E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,25,FALSE,1,Male,6,Incidence,1.4817061986438786E-06,7.996048076403633E-07,5.549020172141758E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,26,TRUE,1,Male,6,Incidence,1.7205441790427554E-06,7.996048076403633E-07,5.549020172141758E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,27,TRUE,1,Male,6,Incidence,1.985422917929943E-06,7.996048076403633E-07,5.549020172141758E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,28,TRUE,1,Male,6,Incidence,2.2752806288219985E-06,7.996048076403633E-07,5.549020172141758E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,29,TRUE,1,Male,6,Incidence,2.5880019626891165E-06,7.996048076403633E-07,5.549020172141758E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,25,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,26,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,27,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,28,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,29,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,25,TRUE,1,Male,15,mortality,0.3726771304644066,0.37245466842080777,0.37245466842080777
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,26,TRUE,1,Male,15,mortality,0.37538151032921013,0.37524756766056233,0.37524756766056233
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,27,TRUE,1,Male,15,mortality,0.3780933595984924,0.378048553,0.378048553
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,28,TRUE,1,Male,15,mortality,0.3808076375508065,0.380852246,0.380852246
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,29,TRUE,1,Male,15,mortality,0.3835191253243761,0.3836532707071094,0.3836532707071094
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,25,FALSE,2,Female,5,Prevalence,2.3463142775777606E-06,2.7069336954095593E-06,1.3344495169723112E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,26,TRUE,2,Female,5,Prevalence,2.6961295421995183E-06,2.7069336954095593E-06,1.3344495169723112E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,27,TRUE,2,Female,5,Prevalence,3.0912576738167926E-06,2.7069336954095593E-06,1.3344495169723112E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,28,TRUE,2,Female,5,Prevalence,3.5374648999433997E-06,2.7069336954095593E-06,1.3344495169723112E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,29,TRUE,2,Female,5,Prevalence,4.040094457044558E-06,2.7069336954095593E-06,1.3344495169723112E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,25,FALSE,2,Female,6,Incidence,1.2777533700845965E-06,8.586587730010684E-07,4.243657546708748E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,26,TRUE,2,Female,6,Incidence,1.472248887278444E-06,8.586587730010684E-07,4.243657546708748E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,27,TRUE,2,Female,6,Incidence,1.693927842813445E-06,8.586587730010684E-07,4.243657546708748E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,28,TRUE,2,Female,6,Incidence,1.946083305597349E-06,8.586587730010684E-07,4.243657546708748E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,29,TRUE,2,Female,6,Incidence,2.2316948843778523E-06,8.586587730010684E-07,4.243657546708748E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,25,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,26,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,27,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,28,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,29,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,25,TRUE,2,Female,15,mortality,0.475170667,0.47270992360471153,0.47270992360471153
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,26,TRUE,2,Female,15,mortality,0.4783801466940965,0.47609682613932014,0.47609682613932014
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,27,TRUE,2,Female,15,mortality,0.48172579389034337,0.47962079966730786,0.47962079966730786
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,28,TRUE,2,Female,15,mortality,0.4851973603914718,0.4832711021803736,0.4832711021803736
826,United Kingdom,Gallbladder and biliary tract cancer,2019,10,25 to 29,29,TRUE,2,Female,15,mortality,0.4887843361391482,0.4870369916702165,0.4870369916702165
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,30,FALSE,1,Male,5,Prevalence,6.3767521730090596E-06,9.44151336646779E-06,5.1566757322379525E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,31,TRUE,1,Male,5,Prevalence,7.166653029514906E-06,9.44151336646779E-06,5.1566757322379525E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,32,TRUE,1,Male,5,Prevalence,7.992926282008492E-06,9.44151336646779E-06,5.1566757322379525E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,33,TRUE,1,Male,5,Prevalence,8.84834026240474E-06,9.44151336646779E-06,5.1566757322379525E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,34,TRUE,1,Male,5,Prevalence,9.727510899966693E-06,9.44151336646779E-06,5.1566757322379525E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,30,FALSE,1,Male,6,Incidence,2.9206564809651643E-06,2.945752009410325E-06,1.6182058702628863E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,31,TRUE,1,Male,6,Incidence,3.2699201177205996E-06,2.945752009410325E-06,1.6182058702628863E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,32,TRUE,1,Male,6,Incidence,3.6326431269924496E-06,2.945752009410325E-06,1.6182058702628863E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,33,TRUE,1,Male,6,Incidence,4.00650187040789E-06,2.945752009410325E-06,1.6182058702628863E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,34,TRUE,1,Male,6,Incidence,4.390655391176161E-06,2.945752009410325E-06,1.6182058702628863E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,30,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,31,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,32,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,33,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,34,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,30,TRUE,1,Male,15,mortality,0.38622251687879205,0.3864462496968831,0.3864462496968831
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,31,TRUE,1,Male,15,mortality,0.3889124655403185,0.38922580577303456,0.38922580577303456
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,32,TRUE,1,Male,15,mortality,0.39158360660805536,0.3919865617951124,0.3919865617951124
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,33,TRUE,1,Male,15,mortality,0.3942305677747017,0.3947231406226658,0.3947231406226658
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,34,TRUE,1,Male,15,mortality,0.3968479736839388,0.397430165,0.397430165
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,30,FALSE,2,Female,5,Prevalence,4.603712397288574E-06,6.103737427849938E-06,2.4751186979825982E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,31,TRUE,2,Female,5,Prevalence,5.231851622510654E-06,6.103737427849938E-06,2.4751186979825982E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,32,TRUE,2,Female,5,Prevalence,5.926896947141937E-06,6.103737427849938E-06,2.4751186979825982E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,33,TRUE,2,Female,5,Prevalence,6.690138045274297E-06,6.103737427849938E-06,2.4751186979825982E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,34,TRUE,2,Female,5,Prevalence,7.521999504577135E-06,6.103737427849938E-06,2.4751186979825982E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,30,FALSE,2,Female,6,Incidence,2.5532781495819557E-06,1.955644815262636E-06,8.16612645563955E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,31,TRUE,2,Female,6,Incidence,2.912799714722581E-06,1.955644815262636E-06,8.16612645563955E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,32,TRUE,2,Female,6,Incidence,3.31167422605368E-06,1.955644815262636E-06,8.16612645563955E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,33,TRUE,2,Female,6,Incidence,3.750851227762503E-06,1.955644815262636E-06,8.16612645563955E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,34,TRUE,2,Female,6,Incidence,4.230991835033856E-06,1.955644815262636E-06,8.16612645563955E-07
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,30,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,31,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,32,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,33,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,34,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,30,TRUE,2,Female,15,mortality,0.49247608317270014,0.4909077261285356,0.4909077261285356
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,31,TRUE,2,Female,15,mortality,0.4962619040133611,0.4948725635470298,0.4948725635470298
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,32,TRUE,2,Female,15,mortality,0.5001310748141149,0.4989207619173981,0.4989207619173981
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,33,TRUE,2,Female,15,mortality,0.5040728606158952,0.5030415792313395,0.5030415792313395
826,United Kingdom,Gallbladder and biliary tract cancer,2019,11,30 to 34,34,TRUE,2,Female,15,mortality,0.5080765220102732,0.507224273,0.507224273
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,35,FALSE,1,Male,5,Prevalence,1.0628325201810104E-05,1.7674524760420478E-05,9.578420651491655E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,36,TRUE,1,Male,5,Prevalence,1.1553200669022981E-05,1.7674524760420478E-05,9.578420651491655E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,37,TRUE,1,Male,5,Prevalence,1.2510034641810214E-05,1.7674524760420478E-05,9.578420651491655E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,38,TRUE,1,Male,5,Prevalence,1.3512749983405902E-05,1.7674524760420478E-05,9.578420651491655E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,39,TRUE,1,Male,5,Prevalence,1.458141062202795E-05,1.7674524760420478E-05,9.578420651491655E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,35,FALSE,1,Male,6,Incidence,4.7863248958179454E-06,5.733997284548678E-06,3.111534927390266E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,36,TRUE,1,Male,6,Incidence,5.197226360858499E-06,5.733997284548678E-06,3.111534927390266E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,37,TRUE,1,Male,6,Incidence,5.629811609775415E-06,5.733997284548678E-06,3.111534927390266E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,38,TRUE,1,Male,6,Incidence,6.093306180905504E-06,5.733997284548678E-06,3.111534927390266E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,39,TRUE,1,Male,6,Incidence,6.5995654951885734E-06,5.733997284548678E-06,3.111534927390266E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,35,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,36,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,37,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,38,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,39,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,35,TRUE,1,Male,15,mortality,0.3994304478199293,0.40010225813239586,0.40010225813239586
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,36,TRUE,1,Male,15,mortality,0.40197261324917855,0.4027340425336706,0.4027340425336706
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,37,TRUE,1,Male,15,mortality,0.4044690928959775,0.40532014117861714,0.40532014117861714
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,38,TRUE,1,Male,15,mortality,0.4069145096389443,0.40785517692678463,0.40785517692678463
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,39,TRUE,1,Male,15,mortality,0.4093034863428993,0.4103337726377223,0.4103337726377223
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,35,FALSE,2,Female,5,Prevalence,8.422440542979417E-06,1.3329467579250237E-05,5.384221043367552E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,36,TRUE,2,Female,5,Prevalence,9.391503082824907E-06,1.3329467579250237E-05,5.384221043367552E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,37,TRUE,2,Female,5,Prevalence,1.0429976514689134E-05,1.3329467579250237E-05,5.384221043367552E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,38,TRUE,2,Female,5,Prevalence,1.1540140122536173E-05,1.3329467579250237E-05,5.384221043367552E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,39,TRUE,2,Female,5,Prevalence,1.2726538403243606E-05,1.3329467579250237E-05,5.384221043367552E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,35,FALSE,2,Female,6,Incidence,4.752728307932577E-06,4.4267546184254986E-06,1.8179649774062727E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,36,TRUE,2,Female,6,Incidence,5.316994380236768E-06,4.4267546184254986E-06,1.8179649774062727E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,37,TRUE,2,Female,6,Incidence,5.925410351614524E-06,4.4267546184254986E-06,1.8179649774062727E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,38,TRUE,2,Female,6,Incidence,6.5807037627553605E-06,4.4267546184254986E-06,1.8179649774062727E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,39,TRUE,2,Female,6,Incidence,7.2871429448415315E-06,4.4267546184254986E-06,1.8179649774062727E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,35,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,36,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,37,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,38,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,39,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,35,TRUE,2,Female,15,mortality,0.5121313178984156,0.5114581026567377,0.5114581026567377
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,36,TRUE,2,Female,15,mortality,0.5162265065731398,0.5157323247515924,0.5157323247515924
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,37,TRUE,2,Female,15,mortality,0.5203513461202813,0.5200361977568164,0.5200361977568164
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,38,TRUE,2,Female,15,mortality,0.5244950945592493,0.5243589796641084,0.5243589796641084
826,United Kingdom,Gallbladder and biliary tract cancer,2019,12,35 to 39,39,TRUE,2,Female,15,mortality,0.5286470098893984,0.5286899284651675,0.5286899284651675
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,40,FALSE,1,Male,5,Prevalence,1.5741946677692638E-05,1.821451314775771E-05,1.0191324543116536E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,41,TRUE,1,Male,5,Prevalence,1.7025578379024623E-05,1.821451314775771E-05,1.0191324543116536E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,42,TRUE,1,Male,5,Prevalence,1.8468049471191083E-05,1.821451314775771E-05,1.0191324543116536E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,43,TRUE,1,Male,5,Prevalence,2.010877174054841E-05,1.821451314775771E-05,1.0191324543116536E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,44,TRUE,1,Male,5,Prevalence,2.198995038269931E-05,1.821451314775771E-05,1.0191324543116536E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,40,FALSE,1,Male,6,Incidence,7.162795971356826E-06,6.464445064335916E-06,3.617561308553985E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,41,TRUE,1,Male,6,Incidence,7.799198405859502E-06,6.464445064335916E-06,3.617561308553985E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,42,TRUE,1,Male,6,Incidence,8.526584945150054E-06,6.464445064335916E-06,3.617561308553985E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,43,TRUE,1,Male,6,Incidence,9.364001718581417E-06,6.464445064335916E-06,3.617561308553985E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,44,TRUE,1,Male,6,Incidence,1.0331365142276829E-05,6.464445064335916E-06,3.617561308553985E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,40,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,41,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,42,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,43,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,44,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,40,TRUE,1,Male,15,mortality,0.41163064586875414,0.4127505511709789,0.4127505511709789
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,41,TRUE,1,Male,15,mortality,0.41389061107638564,0.4151001353861037,0.4151001353861037
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,42,TRUE,1,Male,15,mortality,0.416078005,0.4173771481426456,0.4173771481426456
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,43,TRUE,1,Male,15,mortality,0.4181874499754093,0.41957621230015385,0.41957621230015385
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,44,TRUE,1,Male,15,mortality,0.4202135693859174,0.42169195071817744,0.42169195071817744
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,40,FALSE,2,Female,5,Prevalence,1.3996738787250558E-05,2.1126772368524807E-05,8.32920192305174E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,41,TRUE,2,Female,5,Prevalence,1.5362014607047806E-05,2.1126772368524807E-05,8.32920192305174E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,42,TRUE,2,Female,5,Prevalence,1.6837889166838084E-05,2.1126772368524807E-05,8.32920192305174E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,43,TRUE,2,Female,5,Prevalence,1.8444472099658887E-05,2.1126772368524807E-05,8.32920192305174E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,44,TRUE,2,Female,5,Prevalence,2.0206521347789727E-05,2.1126772368524807E-05,8.32920192305174E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,40,FALSE,2,Female,6,Incidence,8.050956055520114E-06,8.014851486704269E-06,3.185803957744159E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,41,TRUE,2,Female,6,Incidence,8.880702294716684E-06,8.014851486704269E-06,3.185803957744159E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,42,TRUE,2,Female,6,Incidence,9.78755592683867E-06,8.014851486704269E-06,3.185803957744159E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,43,TRUE,2,Female,6,Incidence,1.0785459936302662E-05,8.014851486704269E-06,3.185803957744159E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,44,TRUE,2,Female,6,Incidence,1.189110796721029E-05,8.014851486704269E-06,3.185803957744159E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,40,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,41,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,42,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,43,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,44,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,40,TRUE,2,Female,15,mortality,0.5327963501044053,0.5330183021516928,0.5330183021516928
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,41,TRUE,2,Female,15,mortality,0.5369323731964447,0.537333359,0.537333359
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,42,TRUE,2,Female,15,mortality,0.5410443371573218,0.5416243561479376,0.5416243561479376
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,43,TRUE,2,Female,15,mortality,0.5451214999787569,0.5458805524410552,0.5458805524410552
826,United Kingdom,Gallbladder and biliary tract cancer,2019,13,40 to 44,44,TRUE,2,Female,15,mortality,0.5491531196524534,0.5500912055864348,0.5500912055864348
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,45,FALSE,1,Male,5,Prevalence,2.415572137624968E-05,3.205751527826426E-05,1.6823445952496517E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,46,TRUE,1,Male,5,Prevalence,2.6651305826953605E-05,3.205751527826426E-05,1.6823445952496517E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,47,TRUE,1,Male,5,Prevalence,2.9522186674720383E-05,3.205751527826426E-05,1.6823445952496517E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,48,TRUE,1,Male,5,Prevalence,3.2813342666851165E-05,3.205751527826426E-05,1.6823445952496517E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,49,TRUE,1,Male,5,Prevalence,3.6568620447590934E-05,3.205751527826426E-05,1.6823445952496517E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,45,FALSE,1,Male,6,Incidence,1.1449101993046331E-05,1.2852123343477594E-05,6.788835792296812E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,46,TRUE,1,Male,6,Incidence,1.2737780858639844E-05,1.2852123343477594E-05,6.788835792296812E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,47,TRUE,1,Male,6,Incidence,1.4217738786821446E-05,1.2852123343477594E-05,6.788835792296812E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,48,TRUE,1,Male,6,Incidence,1.590873651408856E-05,1.2852123343477594E-05,6.788835792296812E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,49,TRUE,1,Male,6,Incidence,1.782970502201919E-05,1.2852123343477594E-05,6.788835792296812E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,45,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,46,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,47,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,48,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,49,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,45,TRUE,1,Male,15,mortality,0.42215098591648975,0.42371898625626536,0.42371898625626536
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,46,TRUE,1,Male,15,mortality,0.4239943224266755,0.4256519417739668,0.4256519417739668
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,47,TRUE,1,Male,15,mortality,0.4257382017760238,0.4274854401308308,0.4274854401308308
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,48,TRUE,1,Male,15,mortality,0.4273772468240837,0.42921410418640626,0.42921410418640626
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,49,TRUE,1,Male,15,mortality,0.4289060804304043,0.43083255680024257,0.43083255680024257
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,45,FALSE,2,Female,5,Prevalence,2.215317820210318E-05,3.110675523572142E-05,1.4381199929168837E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,46,TRUE,2,Female,5,Prevalence,2.4317352626895743E-05,3.110675523572142E-05,1.4381199929168837E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,47,TRUE,2,Female,5,Prevalence,2.6734781566653893E-05,3.110675523572142E-05,1.4381199929168837E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,48,TRUE,2,Female,5,Prevalence,2.9442838511750082E-05,3.110675523572142E-05,1.4381199929168837E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,49,TRUE,2,Female,5,Prevalence,3.2479226894736586E-05,3.110675523572142E-05,1.4381199929168837E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,45,FALSE,2,Female,6,Incidence,1.3123723956380016E-05,1.2038596627091607E-05,5.718796083875919E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,46,TRUE,2,Female,6,Incidence,1.4504630391605345E-05,1.2038596627091607E-05,5.718796083875919E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,47,TRUE,2,Female,6,Incidence,1.60566272982257E-05,1.2038596627091607E-05,5.718796083875919E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,48,TRUE,2,Female,6,Incidence,1.78032399307496E-05,1.2038596627091607E-05,5.718796083875919E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,49,TRUE,2,Female,6,Incidence,1.9767925236223194E-05,1.2038596627091607E-05,5.718796083875919E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,45,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,46,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,47,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,48,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,49,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,45,TRUE,2,Female,15,mortality,0.5531284541701108,0.5542455735757756,0.5542455735757756
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,46,TRUE,2,Female,15,mortality,0.5570367615234284,0.5583329144007765,0.5583329144007765
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,47,TRUE,2,Female,15,mortality,0.5608672997041051,0.5623424860531365,0.5623424860531365
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,48,TRUE,2,Female,15,mortality,0.5646093267038399,0.5662635465245547,0.5662635465245547
826,United Kingdom,Gallbladder and biliary tract cancer,2019,14,45 to 49,49,TRUE,2,Female,15,mortality,0.5682521005143318,0.5700853538067299,0.5700853538067299
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,50,FALSE,1,Male,5,Prevalence,4.0830362888019825E-05,4.987758659971874E-05,2.543431535289025E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,51,TRUE,1,Male,5,Prevalence,4.56394115932406E-05,4.987758659971874E-05,2.543431535289025E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,52,TRUE,1,Male,5,Prevalence,5.103554393640733E-05,4.987758659971874E-05,2.543431535289025E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,53,TRUE,1,Male,5,Prevalence,5.7058290632526287E-05,4.987758659971874E-05,2.543431535289025E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,54,TRUE,1,Male,5,Prevalence,6.374793575388781E-05,4.987758659971874E-05,2.543431535289025E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,50,FALSE,1,Male,6,Incidence,1.999865784756741E-05,1.993906649698598E-05,1.0377949361140449E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,51,TRUE,1,Male,6,Incidence,2.243282309439735E-05,1.993906649698598E-05,1.0377949361140449E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,52,TRUE,1,Male,6,Incidence,2.5148992459267543E-05,1.993906649698598E-05,1.0377949361140449E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,53,TRUE,1,Male,6,Incidence,2.8164003077954405E-05,1.993906649698598E-05,1.0377949361140449E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,54,TRUE,1,Male,6,Incidence,3.149518762277857E-05,1.993906649698598E-05,1.0377949361140449E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,50,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,51,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,52,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,53,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,54,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,50,TRUE,1,Male,15,mortality,0.43031932545453455,0.43233542083188836,0.43233542083188836
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,51,TRUE,1,Male,15,mortality,0.4316116047560237,0.4337173191408932,0.4337173191408932
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,52,TRUE,1,Male,15,mortality,0.4327775411944208,0.43497287458680567,0.43497287458680567
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,53,TRUE,1,Male,15,mortality,0.43381175762927476,0.43609671002917505,0.43609671002917505
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,54,TRUE,1,Male,15,mortality,0.43470887692013466,0.43708344832755053,0.43708344832755053
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,50,FALSE,2,Female,5,Prevalence,3.588072760914412E-05,4.5087706887631394E-05,2.113554891821198E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,51,TRUE,2,Female,5,Prevalence,3.9682177025174336E-05,4.5087706887631394E-05,2.113554891821198E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,52,TRUE,2,Female,5,Prevalence,4.391581683716431E-05,4.5087706887631394E-05,2.113554891821198E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,53,TRUE,2,Female,5,Prevalence,4.8611081866047476E-05,4.5087706887631394E-05,2.113554891821198E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,54,TRUE,2,Female,5,Prevalence,5.379479028645349E-05,4.5087706887631394E-05,2.113554891821198E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,50,FALSE,2,Female,6,Incidence,2.1973345215826893E-05,2.030366573099964E-05,9.6518309729985E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,51,TRUE,2,Female,6,Incidence,2.4440810397403345E-05,2.030366573099964E-05,9.6518309729985E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,52,TRUE,2,Female,6,Incidence,2.7189964643643817E-05,2.030366573099964E-05,9.6518309729985E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,53,TRUE,2,Female,6,Incidence,3.0238726970389442E-05,2.030366573099964E-05,9.6518309729985E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,54,TRUE,2,Female,6,Incidence,3.360343878199315E-05,2.030366573099964E-05,9.6518309729985E-06
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,50,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,51,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,52,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,53,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,54,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,50,TRUE,2,Female,15,mortality,0.5717848791272798,0.5737971658913612,0.5737971658913612
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,51,TRUE,2,Female,15,mortality,0.575196921,0.5773882407701477,0.5773882407701477
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,52,TRUE,2,Female,15,mortality,0.5784774827273402,0.5808478364347884,0.5808478364347884
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,53,TRUE,2,Female,15,mortality,0.5816158236978506,0.584165211,0.584165211
826,United Kingdom,Gallbladder and biliary tract cancer,2019,15,50 to 54,54,TRUE,2,Female,15,mortality,0.5846012014376131,0.5873296220884279,0.5873296220884279
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,55,FALSE,1,Male,5,Prevalence,7.114637638408124E-05,0.000107416,5.746002150953972E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,56,TRUE,1,Male,5,Prevalence,7.929747068643132E-05,0.000107416,5.746002150953972E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,57,TRUE,1,Male,5,Prevalence,8.824657438338974E-05,0.000107416,5.746002150953972E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,58,TRUE,1,Male,5,Prevalence,9.803916564429537E-05,0.000107416,5.746002150953972E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,59,TRUE,1,Male,5,Prevalence,0.000108719,0.000107416,5.746002150953972E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,55,FALSE,1,Male,6,Incidence,3.516058266369355E-05,3.850519683322253E-05,2.069366083747832E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,56,TRUE,1,Male,6,Incidence,3.917870452227038E-05,3.850519683322253E-05,2.069366083747832E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,57,TRUE,1,Male,6,Incidence,4.356779813295197E-05,3.850519683322253E-05,2.069366083747832E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,58,TRUE,1,Male,6,Incidence,4.834462374987281E-05,3.850519683322253E-05,2.069366083747832E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,59,TRUE,1,Male,6,Incidence,5.35230274710818E-05,3.850519683322253E-05,2.069366083747832E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,55,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,56,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,57,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,58,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,59,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,55,TRUE,1,Male,15,mortality,0.4354635219265497,0.437927712,0.437927712
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,56,TRUE,1,Male,15,mortality,0.43607031550806874,0.4386241249305156,0.4386241249305156
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,57,TRUE,1,Male,15,mortality,0.4365238805242409,0.4391673089542034,0.4391673089542034
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,58,TRUE,1,Male,15,mortality,0.43681883983461534,0.4395518872720936,0.4395518872720936
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,59,TRUE,1,Male,15,mortality,0.4369498162987411,0.4397724827437348,0.4397724827437348
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,55,FALSE,2,Female,5,Prevalence,5.949159748884038E-05,8.853571796008473E-05,4.517894267263944E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,56,TRUE,2,Female,5,Prevalence,6.572449989826621E-05,8.853571796008473E-05,4.517894267263944E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,57,TRUE,2,Female,5,Prevalence,7.251515475221857E-05,8.853571796008473E-05,4.517894267263944E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,58,TRUE,2,Female,5,Prevalence,7.988382935958897E-05,8.853571796008473E-05,4.517894267263944E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,59,TRUE,2,Female,5,Prevalence,8.7848902904481E-05,8.853571796008473E-05,4.517894267263944E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,55,FALSE,2,Female,6,Incidence,3.729910401284322E-05,4.0290221371857594E-05,2.0961843762144407E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,56,TRUE,2,Female,6,Incidence,4.1339574598070335E-05,4.0290221371857594E-05,2.0961843762144407E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,57,TRUE,2,Female,6,Incidence,4.573753918981757E-05,4.0290221371857594E-05,2.0961843762144407E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,58,TRUE,2,Female,6,Incidence,5.050422334331725E-05,4.0290221371857594E-05,2.0961843762144407E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,59,TRUE,2,Female,6,Incidence,5.564879535661914E-05,4.0290221371857594E-05,2.0961843762144407E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,55,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,56,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,57,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,58,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,59,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,55,TRUE,2,Female,15,mortality,0.5874228739383266,0.5903303280608246,0.5903303280608246
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,56,TRUE,2,Female,15,mortality,0.5900700991916903,0.5931565867858717,0.5931565867858717
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,57,TRUE,2,Female,15,mortality,0.5925321351894031,0.595797656,0.595797656
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,58,TRUE,2,Female,15,mortality,0.59479824,0.598242794,0.598242794
826,United Kingdom,Gallbladder and biliary tract cancer,2019,16,55 to 59,59,TRUE,2,Female,15,mortality,0.596857671,0.6004812593939033,0.6004812593939033
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,60,FALSE,1,Male,5,Prevalence,0.000120325,0.000159857,8.324723853401119E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,61,TRUE,1,Male,5,Prevalence,0.00013289,0.000159857,8.324723853401119E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,62,TRUE,1,Male,5,Prevalence,0.00014644,0.000159857,8.324723853401119E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,63,TRUE,1,Male,5,Prevalence,0.000160998,0.000159857,8.324723853401119E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,64,TRUE,1,Male,5,Prevalence,0.00017658,0.000159857,8.324723853401119E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,60,FALSE,1,Male,6,Incidence,5.9112685740434074E-05,6.124726181389036E-05,3.239262518497464E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,61,TRUE,1,Male,6,Incidence,6.511846311088186E-05,6.124726181389036E-05,3.239262518497464E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,62,TRUE,1,Male,6,Incidence,7.154074007459398E-05,6.124726181389036E-05,3.239262518497464E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,63,TRUE,1,Male,6,Incidence,7.837685474508715E-05,6.124726181389036E-05,3.239262518497464E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,64,TRUE,1,Male,6,Incidence,8.56235014900428E-05,6.124726181389036E-05,3.239262518497464E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,60,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,61,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,62,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,63,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,64,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,60,TRUE,1,Male,15,mortality,0.43691143277616734,0.4398237182286764,0.4398237182286764
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,61,TRUE,1,Male,15,mortality,0.436698312,0.43970021658646763,0.43970021658646763
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,62,TRUE,1,Male,15,mortality,0.4363050772091243,0.4393966006766572,0.4393966006766572
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,63,TRUE,1,Male,15,mortality,0.4357263508837763,0.4389074933587944,0.4389074933587944
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,64,TRUE,1,Male,15,mortality,0.4349567560100324,0.43822751749242816,0.43822751749242816
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,60,FALSE,2,Female,5,Prevalence,9.642598991187687E-05,0.000132372,7.083505753501901E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,61,TRUE,2,Female,5,Prevalence,0.000105627,0.000132372,7.083505753501901E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,62,TRUE,2,Female,5,Prevalence,0.000115459,0.000132372,7.083505753501901E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,63,TRUE,2,Female,5,Prevalence,0.000125923,0.000132372,7.083505753501901E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,64,TRUE,2,Female,5,Prevalence,0.000137018,0.000132372,7.083505753501901E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,60,FALSE,2,Female,6,Incidence,6.117757211188409E-05,6.41338412136362E-05,3.522695628337586E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,61,TRUE,2,Female,6,Incidence,6.709320518781254E-05,6.41338412136362E-05,3.522695628337586E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,62,TRUE,2,Female,6,Incidence,7.339407172761255E-05,6.41338412136362E-05,3.522695628337586E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,63,TRUE,2,Female,6,Incidence,8.007407873248247E-05,6.41338412136362E-05,3.522695628337586E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,64,TRUE,2,Female,6,Incidence,8.712301007873593E-05,6.41338412136362E-05,3.522695628337586E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,60,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,61,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,62,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,63,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,64,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,60,TRUE,2,Female,15,mortality,0.5986996875656264,0.6025023090465409,0.6025023090465409
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,61,TRUE,2,Female,15,mortality,0.6003135464577273,0.6042952014103233,0.6042952014103233
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,62,TRUE,2,Female,15,mortality,0.6016885060526792,0.605849194,0.605849194
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,63,TRUE,2,Female,15,mortality,0.6028138243422082,0.6071535462381197,0.6071535462381197
826,United Kingdom,Gallbladder and biliary tract cancer,2019,17,60 to 64,64,TRUE,2,Female,15,mortality,0.603678759,0.6081975146855314,0.6081975146855314
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,65,FALSE,1,Male,5,Prevalence,0.000193209,0.00031689,0.000162848
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,66,TRUE,1,Male,5,Prevalence,0.000210913,0.00031689,0.000162848
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,67,TRUE,1,Male,5,Prevalence,0.000229734,0.00031689,0.000162848
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,68,TRUE,1,Male,5,Prevalence,0.000249728,0.00031689,0.000162848
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,69,TRUE,1,Male,5,Prevalence,0.000270967,0.00031689,0.000162848
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,65,FALSE,1,Male,6,Incidence,9.327961535376938E-05,0.00011376,6.0484453745791095E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,66,TRUE,1,Male,6,Incidence,0.000101349,0.00011376,6.0484453745791095E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,67,TRUE,1,Male,6,Incidence,0.000109842,0.00011376,6.0484453745791095E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,68,TRUE,1,Male,6,Incidence,0.000118775,0.00011376,6.0484453745791095E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,69,TRUE,1,Male,6,Incidence,0.000128169,0.00011376,6.0484453745791095E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,65,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,66,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,67,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,68,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,69,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,65,TRUE,1,Male,15,mortality,0.4339909154477781,0.43735129593710764,0.43735129593710764
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,66,TRUE,1,Male,15,mortality,0.4328234520578382,0.43627345155238184,0.43627345155238184
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,67,TRUE,1,Male,15,mortality,0.4314489887043032,0.43498860719779997,0.43498860719779997
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,68,TRUE,1,Male,15,mortality,0.42986214826197106,0.433491386,0.433491386
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,69,TRUE,1,Male,15,mortality,0.4280575536388076,0.43177641001726375,0.43177641001726375
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,65,FALSE,2,Female,5,Prevalence,0.000148736,0.00022044,0.000119177
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,66,TRUE,2,Female,5,Prevalence,0.000161069,0.00022044,0.000119177
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,67,TRUE,2,Female,5,Prevalence,0.000174009,0.00022044,0.000119177
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,68,TRUE,2,Female,5,Prevalence,0.000187548,0.00022044,0.000119177
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,69,TRUE,2,Female,5,Prevalence,0.000201685,0.00022044,0.000119177
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,65,FALSE,2,Female,6,Incidence,9.452741520002689E-05,0.000105521,5.9306057812066763E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,66,TRUE,2,Female,6,Incidence,0.000102272,0.000105521,5.9306057812066763E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,67,TRUE,2,Female,6,Incidence,0.00011034,0.000105521,5.9306057812066763E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,68,TRUE,2,Female,6,Incidence,0.000118717,0.000105521,5.9306057812066763E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,69,TRUE,2,Female,6,Incidence,0.000127388,0.000105521,5.9306057812066763E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,65,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,66,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,67,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,68,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,69,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,65,TRUE,2,Female,15,mortality,0.6042725689726147,0.6089703578108845,0.6089703578108845
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,66,TRUE,2,Female,15,mortality,0.6045845112991487,0.6094613336058776,0.6094613336058776
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,67,TRUE,2,Female,15,mortality,0.6046038442957942,0.6096597000622095,0.6096597000622095
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,68,TRUE,2,Female,15,mortality,0.6043198259756147,0.6095547151715798,0.6095547151715798
826,United Kingdom,Gallbladder and biliary tract cancer,2019,18,65 to 69,69,TRUE,2,Female,15,mortality,0.6037217143981466,0.6091356369256872,0.6091356369256872
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,70,FALSE,1,Male,5,Prevalence,0.00029353,0.000405702,0.000223156
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,71,TRUE,1,Male,5,Prevalence,0.000317495,0.000405702,0.000223156
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,72,TRUE,1,Male,5,Prevalence,0.000342918,0.000405702,0.000223156
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,73,TRUE,1,Male,5,Prevalence,0.000369815,0.000405702,0.000223156
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,74,TRUE,1,Male,5,Prevalence,0.00039813,0.000405702,0.000223156
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,70,FALSE,1,Male,6,Incidence,0.000138041,0.000163437,8.980527748579522E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,71,TRUE,1,Male,6,Incidence,0.000148399,0.000163437,8.980527748579522E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,72,TRUE,1,Male,6,Incidence,0.000159229,0.000163437,8.980527748579522E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,73,TRUE,1,Male,6,Incidence,0.000170485,0.000163437,8.980527748579522E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,74,TRUE,1,Male,6,Incidence,0.00018207,0.000163437,8.980527748579522E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,70,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,71,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,72,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,73,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,74,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,70,TRUE,1,Male,15,mortality,0.4260298278401177,0.4298383029104077,0.4298383029104077
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,71,TRUE,1,Male,15,mortality,0.42377359414241816,0.42767168727189175,0.42767168727189175
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,72,TRUE,1,Male,15,mortality,0.4212834765410623,0.4252711859612649,0.4252711859612649
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,73,TRUE,1,Male,15,mortality,0.4185541008468508,0.42263142183807634,0.42263142183807634
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,74,TRUE,1,Male,15,mortality,0.41558009724597195,0.41974701776187484,0.41974701776187484
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,70,FALSE,2,Female,5,Prevalence,0.000216418,0.000313795,0.000174066
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,71,TRUE,2,Female,5,Prevalence,0.000231745,0.000313795,0.000174066
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,72,TRUE,2,Female,5,Prevalence,0.00024766,0.000313795,0.000174066
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,73,TRUE,2,Female,5,Prevalence,0.000264139,0.000313795,0.000174066
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,74,TRUE,2,Female,5,Prevalence,0.000281134,0.000313795,0.000174066
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,70,FALSE,2,Female,6,Incidence,0.000136336,0.000154433,8.804435331675099E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,71,TRUE,2,Female,6,Incidence,0.000145543,0.000154433,8.804435331675099E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,72,TRUE,2,Female,6,Incidence,0.000154982,0.000154433,8.804435331675099E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,73,TRUE,2,Female,6,Incidence,0.000164614,0.000154433,8.804435331675099E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,74,TRUE,2,Female,6,Incidence,0.000174374,0.000154433,8.804435331675099E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,70,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,71,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,72,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,73,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,74,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,70,TRUE,2,Female,15,mortality,0.602798768,0.6083917233162307,0.6083917233162307
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,71,TRUE,2,Female,15,mortality,0.601540245,0.607312232,0.607312232
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,72,TRUE,2,Female,15,mortality,0.5999354046084631,0.6058864219734216,0.6058864219734216
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,73,TRUE,2,Female,15,mortality,0.5979735098065477,0.6041035502234674,0.6041035502234674
826,United Kingdom,Gallbladder and biliary tract cancer,2019,19,70 to 74,74,TRUE,2,Female,15,mortality,0.5956438284871602,0.6019528750767453,0.6019528750767453
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,75,FALSE,1,Male,5,Prevalence,0.000427705,0.000612379,0.000348204
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,76,TRUE,1,Male,5,Prevalence,0.000458249,0.000612379,0.000348204
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,77,TRUE,1,Male,5,Prevalence,0.00048931,0.000612379,0.000348204
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,78,TRUE,1,Male,5,Prevalence,0.000520254,0.000612379,0.000348204
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,79,TRUE,1,Male,5,Prevalence,0.000550255,0.000612379,0.000348204
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,75,FALSE,1,Male,6,Incidence,0.000193823,0.00023964,0.000139779
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,76,TRUE,1,Male,6,Incidence,0.000205511,0.00023964,0.000139779
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,77,TRUE,1,Male,6,Incidence,0.000216814,0.00023964,0.000139779
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,78,TRUE,1,Male,6,Incidence,0.000227332,0.00023964,0.000139779
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,79,TRUE,1,Male,6,Incidence,0.000236589,0.00023964,0.000139779
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,75,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,76,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,77,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,78,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,79,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,75,TRUE,1,Male,15,mortality,0.4123561060007532,0.41661259659220984,0.41661259659220984
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,76,TRUE,1,Male,15,mortality,0.4088767895712792,0.4132227811886303,0.4132227811886303
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,77,TRUE,1,Male,15,mortality,0.4051368572434278,0.40957219441068504,0.40957219441068504
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,78,TRUE,1,Male,15,mortality,0.4011311129662576,0.40565545911792356,0.40565545911792356
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,79,TRUE,1,Male,15,mortality,0.3968545442126234,0.4014671981698943,0.4014671981698943
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,75,FALSE,2,Female,5,Prevalence,0.000298559,0.000428497,0.000223727
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,76,TRUE,2,Female,5,Prevalence,0.000316272,0.000428497,0.000223727
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,77,TRUE,2,Female,5,Prevalence,0.000334068,0.000428497,0.000223727
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,78,TRUE,2,Female,5,Prevalence,0.000351664,0.000428497,0.000223727
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,79,TRUE,2,Female,5,Prevalence,0.0003687,0.000428497,0.000223727
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,75,FALSE,2,Female,6,Incidence,0.000184171,0.000220311,0.000120361
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,76,TRUE,2,Female,6,Incidence,0.000193873,0.000220311,0.000120361
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,77,TRUE,2,Female,6,Incidence,0.000203303,0.000220311,0.000120361
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,78,TRUE,2,Female,6,Incidence,0.000212239,0.000220311,0.000120361
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,79,TRUE,2,Female,6,Incidence,0.000220412,0.000220311,0.000120361
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,75,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,76,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,77,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,78,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,79,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,75,TRUE,2,Female,15,mortality,0.5929356430274856,0.5994236545249543,0.5994236545249543
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,76,TRUE,2,Female,15,mortality,0.5898382669103938,0.5965051465597931,0.5965051465597931
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,77,TRUE,2,Female,15,mortality,0.5863410792375995,0.5931866091729611,0.5931866091729611
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,78,TRUE,2,Female,15,mortality,0.5824335917705145,0.5894573003561574,0.5894573003561574
826,United Kingdom,Gallbladder and biliary tract cancer,2019,20,75 to 79,79,TRUE,2,Female,15,mortality,0.5781055734680837,0.5853064781010806,0.5853064781010806
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,80,FALSE,1,Male,5,Prevalence,0.000578313,0.000841763,0.000498772
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,81,TRUE,1,Male,5,Prevalence,0.000603291,0.000841763,0.000498772
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,82,TRUE,1,Male,5,Prevalence,0.00062398,0.000841763,0.000498772
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,83,TRUE,1,Male,5,Prevalence,0.000639189,0.000841763,0.000498772
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,84,TRUE,1,Male,5,Prevalence,0.000647855,0.000841763,0.000498772
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,80,FALSE,1,Male,6,Incidence,0.000244059,0.00033112,0.000198883
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,81,TRUE,1,Male,6,Incidence,0.000249202,0.00033112,0.000198883
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,82,TRUE,1,Male,6,Incidence,0.000251513,0.00033112,0.000198883
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,83,TRUE,1,Male,6,Incidence,0.00025058,0.00033112,0.000198883
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,84,TRUE,1,Male,6,Incidence,0.00024614,0.00033112,0.000198883
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,80,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,81,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,82,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,83,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,84,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,80,TRUE,1,Male,15,mortality,0.3923024798455917,0.3970020344261471,0.3970020344261471
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,81,TRUE,1,Male,15,mortality,0.38747085829861105,0.3922545907462305,0.3922545907462305
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,82,TRUE,1,Male,15,mortality,0.38235666298469534,0.38721948998969347,0.38721948998969347
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,83,TRUE,1,Male,15,mortality,0.37695859729467124,0.3818913550160856,0.3818913550160856
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,84,TRUE,1,Male,15,mortality,0.3712780823118418,0.3762648086849556,0.3762648086849556
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,80,FALSE,2,Female,5,Prevalence,0.000384739,0.000569233,0.000275614
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,81,TRUE,2,Female,5,Prevalence,0.000399284,0.000569233,0.000275614
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,82,TRUE,2,Female,5,Prevalence,0.000411799,0.000569233,0.000275614
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,83,TRUE,2,Female,5,Prevalence,0.000421746,0.000569233,0.000275614
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,84,TRUE,2,Female,5,Prevalence,0.000428624,0.000569233,0.000275614
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,80,FALSE,2,Female,6,Incidence,0.000227516,0.000301315,0.000151559
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,81,TRUE,2,Female,6,Incidence,0.000233224,0.000301315,0.000151559
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,82,TRUE,2,Female,6,Incidence,0.000237209,0.000301315,0.000151559
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,83,TRUE,2,Female,6,Incidence,0.000239174,0.000301315,0.000151559
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,84,TRUE,2,Female,6,Incidence,0.000238881,0.000301315,0.000151559
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,80,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,81,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,82,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,83,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,84,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,80,TRUE,2,Female,15,mortality,0.5733472717479363,0.5807234003994302,0.5807234003994302
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,81,TRUE,2,Female,15,mortality,0.568149788,0.5756973252429048,0.5756973252429048
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,82,TRUE,2,Female,15,mortality,0.5625056898514806,0.570217511,0.570217511
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,83,TRUE,2,Female,15,mortality,0.556409954,0.5642732145320248,0.5642732145320248
826,United Kingdom,Gallbladder and biliary tract cancer,2019,30,80 to 84,84,TRUE,2,Female,15,mortality,0.5498613669465936,0.5578536949610686,0.5578536949610686
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,85,FALSE,1,Male,5,Prevalence,0.000649152,0.001250836,0.000753239
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,86,TRUE,1,Male,5,Prevalence,0.0006426,0.001250836,0.000753239
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,87,TRUE,1,Male,5,Prevalence,0.00062814,0.001250836,0.000753239
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,88,TRUE,1,Male,5,Prevalence,0.000606175,0.001250836,0.000753239
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,89,TRUE,1,Male,5,Prevalence,0.000577563,0.001250836,0.000753239
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,85,FALSE,1,Male,6,Incidence,0.000238126,0.00052566,0.000325692
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,86,TRUE,1,Male,6,Incidence,0.000226704,0.00052566,0.000325692
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,87,TRUE,1,Male,6,Incidence,0.000212276,0.00052566,0.000325692
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,88,TRUE,1,Male,6,Incidence,0.000195461,0.00052566,0.000325692
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,89,TRUE,1,Male,6,Incidence,0.000177046,0.00052566,0.000325692
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,85,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,86,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,87,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,88,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,89,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,85,TRUE,1,Male,15,mortality,0.3653206597660519,0.3703344738558525,0.3703344738558525
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,86,TRUE,1,Male,15,mortality,0.3590978625428936,0.3640949733883255,0.3640949733883255
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,87,TRUE,1,Male,15,mortality,0.35262956717291666,0.35754093014192345,0.35754093014192345
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,88,TRUE,1,Male,15,mortality,0.34594676199808966,0.3506669669761959,0.3506669669761959
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,89,TRUE,1,Male,15,mortality,0.33909455239551817,0.3434677067506914,0.3434677067506914
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,85,FALSE,2,Female,5,Prevalence,0.000432017,0.000758716,0.000341068
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,86,TRUE,2,Female,5,Prevalence,0.000431635,0.000758716,0.000341068
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,87,TRUE,2,Female,5,Prevalence,0.000427353,0.000758716,0.000341068
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,88,TRUE,2,Female,5,Prevalence,0.000419239,0.000758716,0.000341068
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,89,TRUE,2,Female,5,Prevalence,0.000407558,0.000758716,0.000341068
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,85,FALSE,2,Female,6,Incidence,0.000236179,0.000440737,0.000213328
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,86,TRUE,2,Female,6,Incidence,0.000231034,0.000440737,0.000213328
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,87,TRUE,2,Female,6,Incidence,0.000223541,0.000440737,0.000213328
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,88,TRUE,2,Female,6,Incidence,0.000213934,0.000440737,0.000213328
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,89,TRUE,2,Female,6,Incidence,0.000202574,0.000440737,0.000213328
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,85,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,86,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,87,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,88,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,89,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,85,TRUE,2,Female,15,mortality,0.5428644943498581,0.5509482099020334,0.5509482099020334
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,86,TRUE,2,Female,15,mortality,0.5354323009522947,0.5435460173466184,0.5435460173466184
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,87,TRUE,2,Female,15,mortality,0.5275894529254423,0.5356363752865223,0.5356363752865223
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,88,TRUE,2,Female,15,mortality,0.5193762025002758,0.5272085417134443,0.5272085417134443
826,United Kingdom,Gallbladder and biliary tract cancer,2019,31,85 to 89,89,TRUE,2,Female,15,mortality,0.5108526081783401,0.5182517746190836,0.5182517746190836
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,90,FALSE,1,Male,5,Prevalence,0.000543558,0.000415459,0.000260314
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,91,TRUE,1,Male,5,Prevalence,0.000505719,0.000415459,0.000260314
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,92,TRUE,1,Male,5,Prevalence,0.000465783,0.000415459,0.000260314
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,93,TRUE,1,Male,5,Prevalence,0.000425534,0.000415459,0.000260314
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,94,TRUE,1,Male,5,Prevalence,0.00038668,0.000415459,0.000260314
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,90,FALSE,1,Male,6,Incidence,0.000157915,0.00033088,0.000207269
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,91,TRUE,1,Male,6,Incidence,0.000138974,0.00033088,0.000207269
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,92,TRUE,1,Male,6,Incidence,0.000121066,0.00033088,0.000207269
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,93,TRUE,1,Male,6,Incidence,0.000104907,0.00033088,0.000207269
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,94,TRUE,1,Male,6,Incidence,9.104330513580786E-05,0.00033088,0.000207269
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,90,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,91,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,92,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,93,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,94,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,90,TRUE,1,Male,15,mortality,0.33213509141927017,0.33593777232495925,0.33593777232495925
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,91,TRUE,1,Male,15,mortality,0.32514999268000766,0.3280717865585484,0.3280717865585484
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,92,TRUE,1,Male,15,mortality,0.3182416843316361,0.31986437231100806,0.31986437231100806
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,93,TRUE,1,Male,15,mortality,0.31153313543984207,0.3113101524418872,0.3113101524418872
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,94,TRUE,1,Male,15,mortality,0.3051654612059034,0.3024037498107349,0.3024037498107349
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,90,FALSE,2,Female,5,Prevalence,0.000392774,0.000460759,0.00021015
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,91,TRUE,2,Female,5,Prevalence,0.000375521,0.000460759,0.00021015
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,92,TRUE,2,Female,5,Prevalence,0.000356566,0.000460759,0.00021015
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,93,TRUE,2,Female,5,Prevalence,0.000336766,0.000460759,0.00021015
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,94,TRUE,2,Female,5,Prevalence,0.000317016,0.000460759,0.00021015
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,90,FALSE,2,Female,6,Incidence,0.00018993,0.000409701,0.000189069
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,91,TRUE,2,Female,6,Incidence,0.000176547,0.000409701,0.000189069
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,92,TRUE,2,Female,6,Incidence,0.000163008,0.000409701,0.000189069
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,93,TRUE,2,Female,6,Incidence,0.000149891,0.000409701,0.000189069
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,94,TRUE,2,Female,6,Incidence,0.000137734,0.000409701,0.000189069
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,90,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,91,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,92,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,93,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,94,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,90,TRUE,2,Female,15,mortality,0.5021026543769366,0.5087553319951388,0.5087553319951388
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,91,TRUE,2,Female,15,mortality,0.4932376504537557,0.49870847183330913,0.49870847183330913
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,92,TRUE,2,Female,15,mortality,0.48439815168824585,0.4881004521252936,0.4881004521252936
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,93,TRUE,2,Female,15,mortality,0.4757536058418604,0.47692053086279107,0.47692053086279107
826,United Kingdom,Gallbladder and biliary tract cancer,2019,32,90 to 94,94,TRUE,2,Female,15,mortality,0.46749903381113894,0.4651579660375008,0.4651579660375008
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,95,FALSE,1,Male,5,Prevalence,0.000350756,0.000192906,0.000109191
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,96,TRUE,1,Male,5,Prevalence,0.000319057,0.000192906,0.000109191
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,97,TRUE,1,Male,5,Prevalence,0.000292611,0.000192906,0.000109191
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,98,TRUE,1,Male,5,Prevalence,0.000272182,0.000192906,0.000109191
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,99,TRUE,1,Male,5,Prevalence,0.000258297,0.000192906,0.000109191
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,100,TRUE,1,Male,5,Prevalence,0.000251278,0.000192906,0.000109191
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,95,FALSE,1,Male,6,Incidence,7.983762110540504E-05,0.000344851,0.000195303
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,96,TRUE,1,Male,6,Incidence,7.147528018218174E-05,0.000344851,0.000195303
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,97,TRUE,1,Male,6,Incidence,6.59974356490995E-05,0.000344851,0.000195303
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,98,TRUE,1,Male,6,Incidence,6.334307568943197E-05,0.000344851,0.000195303
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,99,TRUE,1,Male,6,Incidence,6.339298707100977E-05,0.000344851,0.000195303
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,100,TRUE,1,Male,6,Incidence,6.600609193572366E-05,0.000344851,0.000195303
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,95,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,96,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,97,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,98,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,99,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,100,TRUE,1,Male,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,95,TRUE,1,Male,15,mortality,0.2992931086613959,0.2931397872771003,0.2931397872771003
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,96,TRUE,1,Male,15,mortality,0.2940766315675951,0.2835128877005324,0.2835128877005324
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,97,TRUE,1,Male,15,mortality,0.2896734442551668,0.27351767394058024,0.27351767394058024
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,98,TRUE,1,Male,15,mortality,0.28622733366154945,0.26314876885679284,0.26314876885679284
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,99,TRUE,1,Male,15,mortality,0.2838578259448398,0.2524007953087194,0.2524007953087194
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,100,TRUE,1,Male,15,mortality,0.28265067097347885,0.24126837615590901,0.24126837615590901
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,95,FALSE,2,Female,5,Prevalence,0.000298196,0.000218815,9.293219970522917E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,96,TRUE,2,Female,5,Prevalence,0.000281132,0.000218815,9.293219970522917E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,97,TRUE,2,Female,5,Prevalence,0.000266554,0.000218815,9.293219970522917E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,98,TRUE,2,Female,5,Prevalence,0.00025507,0.000218815,9.293219970522917E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,99,TRUE,2,Female,5,Prevalence,0.000247148,0.000218815,9.293219970522917E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,100,TRUE,2,Female,5,Prevalence,0.000243108,0.000218815,9.293219970522917E-05
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,95,FALSE,2,Female,6,Incidence,0.000127,0.000409767,0.000175335
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,96,TRUE,2,Female,6,Incidence,0.000118061,0.000409767,0.000175335
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,97,TRUE,2,Female,6,Incidence,0.000111188,0.000409767,0.000175335
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,98,TRUE,2,Female,6,Incidence,0.00010655,0.000409767,0.000175335
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,99,TRUE,2,Female,6,Incidence,0.000104231,0.000409767,0.000175335
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,100,TRUE,2,Female,6,Incidence,0.000104235,0.000409767,0.000175335
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,95,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,96,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,97,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,98,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,99,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,100,TRUE,2,Female,7,remission,0,0,0
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,95,TRUE,2,Female,15,mortality,0.4598483256746581,0.4528020156411212,0.4528020156411212
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,96,TRUE,2,Female,15,mortality,0.45302416300954623,0.4398419376653524,0.4398419376653524
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,97,TRUE,2,Female,15,mortality,0.4472451114367228,0.42626699010189206,0.42626699010189206
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,98,TRUE,2,Female,15,mortality,0.4427109724828964,0.4120664309424398,0.4120664309424398
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,99,TRUE,2,Female,15,mortality,0.43958792776665484,0.3972295181786947,0.3972295181786947
826,United Kingdom,Gallbladder and biliary tract cancer,2019,235,95 to 110,100,TRUE,2,Female,15,mortality,0.4379952423211024,0.38174550980235633,0.38174550980235633
